# Ra Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ra-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.rapharma.com
- Total disclosed funding: $67M
- Latest round: Series B (Jul 24, 2015)
- Investors on record: 9

## About

Ra Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases, leveraging proprietary technologies for precise therapeutic solutions.Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, US. The company specializes in developing therapeutic products for rare diseases. It successfully raised USD 92 mn in an IPO on October 25, 2016, marking a significant milestone in its funding journey. Details on the founder’s history are not available, and there is no mention of subsidiaries or parent companies.Ra Pharmaceuticals, Inc. develops innovative biopharmaceutical solutions aimed at treating rare diseases. The company focuses on utilizing proprietary technologies to create novel therapeutic products that address specific patient needs and improve treatment outcomes. Ra Pharma's client base includes healthcare providers and patients, particularly in regions where rare diseases pose a significant health challenge.In the most recent financial year, 2019, Ra Pharmaceuticals, Inc. reported revenue of USD 3 mn, with an EBITDA loss of USD 105.36 mn for the same period.Ra Pharmaceuticals, Inc. plans to utilize the proceeds from its recent IPO to accelerate the development and commercialization of its product pipeline. Future growth initiatives include launching new therapeutic products targeting rare diseases and expanding into new geographic markets. Specific regions targeted for expansion have not been disclosed, but the company aims for strategic international outreach within the next few years.

## Funding rounds

- Series B, Jul 24, 2015, $59M — Morgenthaler Ventures, New Enterprise Associates, Novartis Venture Fund, Amgen Ventures, Novo Holdings, Lightstone Ventures, RA Capital Management, Rock Springs Capital, Limulus Venture Partners
- Series A, May 16, 2012, $8.6M — Morgenthaler Ventures, New Enterprise Associates, Novartis Venture Fund, Amgen Ventures

## Investors

- Morgenthaler Ventures (https://capitalatlas.ai/funds/morgenthaler-ventures) — Series A, Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A, Series B
- Novo Holdings — Series B
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Rock Springs Capital — Series B
- Limulus Venture Partners (https://capitalatlas.ai/funds/limulus-venture-partners) — Series B